Xbrane Biopharma AB has disclosed progress for its Biogen-partnered BIIB801 proposed biosimilar to Cimzia (certolizumab pegol), producing the first drug substance scale-up batch with the firm’s contract manufacturer ahead of plans to produce good manufacturing practice batches during the end of 2024 and beginning of 2025.
Should these endeavours prove fruitful, Xbrane intends to use the batches in a planned upcoming clinical trial,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?